Medication-Attributable Adverse Events in Heart Failure Trials

By sjmartinez • March 8, 2023

Harrington J, Fonarow GC, Khan MS, Hernandez A, Anker S, Böhm M, Greene SJ, Felker GM, Vaduganathan M, Butler J. Medication-Attributable Adverse Events in Heart Failure Trials. JACC Heart Fail. 2023 Jan 12:S2213-1779(22)00721-1. doi: 10.1016/j.jchf.2022.11.026. Epub ahead of print. PMID: 36881395.

Tags: Adverse events, Cardiology/Epi, Guideline-directed medical therapy, heart failure, Publications

Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and de novo lipogenesis

Talari NK, Mattam U, Kaminska D, Sotomayor-Rodriguez I, Rahman AP, Péterfy M, Pajukanta P, Pihlajamäki J, Chella Krishnan K. Hepatokine ITIH3 protects against hepatic steatosis[...]

A Leaky False Pouch: Left Ventricle Pseudoaneurysm with Active Hemopericardium Detected on Cardiac Computed Tomography Angiography

Barforoshi S, Shekar C, Yu Z, Liu E, Manubolu V, Budoff MJ, Roy SK. A Leaky False Pouch: Left Ventricle Pseudoaneurysm with Active Hemopericardium Detected[...]

Contemporary Decongestion Strategies in Patients Hospitalized for Heart Failure: A National Community-Based Cohort Study

Zheng J, Ambrosy AP, Bhatt AS, Collins SP, Flint KM, Fonarow GC, Fudim M, Greene SJ, Lala A, Testani JM, Varshney AS, Wi RSK, Sandhu[...]